Serveur d'exploration sur la grippe en France

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.

Identifieur interne : 000336 ( Main/Exploration ); précédent : 000335; suivant : 000337

Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.

Auteurs : Guillaume Moulis [France] ; Agnès Sommet ; Laurent Sailler ; Maryse Lapeyre-Mestre ; Jean-Louis Montastruc

Source :

RBID : pubmed:22098130

Descripteurs français

English descriptors

Abstract

The aim of this survey was to describe drug-induced immune thrombocytopenia (ITP) reported in the French PharmacoVigilance database (FPVD) and to discuss the drugs involved. The request to the FPVD used the seven most accurate diagnosis codes to identify ITP. The study was restricted to cases reported from 2007 to 2010 and at least "possible" according to the French causality assessment score. We then described the population's characteristics, the drugs involved, the clinical symptoms, and the course of ITP. For each drug, we estimated the causality assessment score developed by George for drug-induced ITP. We included 59 drug-induced ITP. Among them, 45.8% were post-vaccinal: they mainly occurred in children (median age: 16 years). Main vaccines were diphtheria-tetanus-poliomyelitis (DTP, 9 cases), influenza (n=8) and measles, mumps, and rubella (MMR, n=7). Regarding the 33 non-vaccinal cases: some drugs are well-known as triggering ITP (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), n=5; abciximab, n=4, acetaminophen, n=2). Other drugs inducing ITP were involved, like serotonin reuptake inhibitors or bevacizumab. Mean age was 57.1 ± 21.7; 60.6% of the patients were male and 25% had autoimmune antecedents. Among the 55 suspected drugs, three were classified as "probable" and 28 as "possible" according to George scale. In both vaccinal and other cases, median delay was 14 days, median platelet value at nadir was<10000 µl(-1) and hemorrhagic symptoms were rarely severe (only 2 gastrointestinal hemorrhages). Specific treatment was introduced in 45 (76.3%) patients. Five drug-induced cases led to chronicity. Among them, ezetimibe was suspected in two reports. In the FPVD, DTP, MMR, and influenza vaccines are the most often reported vaccines inducing ITP, perhaps because of their wide use. Our study confirmed that NSAIDs, abciximab, and acetaminophen frequently trigger ITP. It also allows to suspect other drugs like serotonin reuptake inhibitors or bevacizumab. Ezetimibe may induce chronic ITP. Drug-induced ITP is rarely severe. Finally, this study also shows that chronicity of ITP does not rule out the possibility of an iatrogenic cause.

DOI: 10.3109/09537104.2011.633179
PubMed: 22098130


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.</title>
<author>
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Internal Medicine, Toulouse University Hospital, Toulouse, France. guillaume.moulis@univ-tlse3.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Toulouse University Hospital, Toulouse</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name>
</author>
<author>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
</author>
<author>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22098130</idno>
<idno type="pmid">22098130</idno>
<idno type="doi">10.3109/09537104.2011.633179</idno>
<idno type="wicri:Area/Main/Corpus">000346</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000346</idno>
<idno type="wicri:Area/Main/Curation">000346</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000346</idno>
<idno type="wicri:Area/Main/Exploration">000346</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.</title>
<author>
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Internal Medicine, Toulouse University Hospital, Toulouse, France. guillaume.moulis@univ-tlse3.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Toulouse University Hospital, Toulouse</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name>
</author>
<author>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
</author>
<author>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</analytic>
<series>
<title level="j">Platelets</title>
<idno type="eISSN">1369-1635</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent (MeSH)</term>
<term>Adverse Drug Reaction Reporting Systems (MeSH)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (adverse effects)</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antibodies, Monoclonal (adverse effects)</term>
<term>Blood Platelets (drug effects)</term>
<term>Blood Platelets (pathology)</term>
<term>Causality (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Databases, Pharmaceutical (MeSH)</term>
<term>Female (MeSH)</term>
<term>France (epidemiology)</term>
<term>Health Surveys (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Pharmacovigilance (MeSH)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (chemically induced)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (diagnosis)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (epidemiology)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (pathology)</term>
<term>Research Design (MeSH)</term>
<term>Serotonin Uptake Inhibitors (administration & dosage)</term>
<term>Serotonin Uptake Inhibitors (adverse effects)</term>
<term>Vaccines (administration & dosage)</term>
<term>Vaccines (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent (MeSH)</term>
<term>Anti-inflammatoires non stéroïdiens (administration et posologie)</term>
<term>Anti-inflammatoires non stéroïdiens (effets indésirables)</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Anticorps monoclonaux (effets indésirables)</term>
<term>Bases de données pharmaceutiques (MeSH)</term>
<term>Causalité (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Enquêtes de santé (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>France (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Inhibiteurs de la capture de la sérotonine (administration et posologie)</term>
<term>Inhibiteurs de la capture de la sérotonine (effets indésirables)</term>
<term>Mâle (MeSH)</term>
<term>Pharmacovigilance (MeSH)</term>
<term>Plan de recherche (MeSH)</term>
<term>Plaquettes (anatomopathologie)</term>
<term>Plaquettes (effets des médicaments et des substances chimiques)</term>
<term>Purpura thrombopénique idiopathique (anatomopathologie)</term>
<term>Purpura thrombopénique idiopathique (diagnostic)</term>
<term>Purpura thrombopénique idiopathique (induit chimiquement)</term>
<term>Purpura thrombopénique idiopathique (épidémiologie)</term>
<term>Systèmes de signalement des effets indésirables des médicaments (MeSH)</term>
<term>Vaccins (administration et posologie)</term>
<term>Vaccins (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Antibodies, Monoclonal</term>
<term>Serotonin Uptake Inhibitors</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Antibodies, Monoclonal</term>
<term>Serotonin Uptake Inhibitors</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Anti-inflammatoires non stéroïdiens</term>
<term>Anticorps monoclonaux</term>
<term>Inhibiteurs de la capture de la sérotonine</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Plaquettes</term>
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Blood Platelets</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Plaquettes</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Anti-inflammatoires non stéroïdiens</term>
<term>Anticorps monoclonaux</term>
<term>Inhibiteurs de la capture de la sérotonine</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr">
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Blood Platelets</term>
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>France</term>
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adverse Drug Reaction Reporting Systems</term>
<term>Causality</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Databases, Pharmaceutical</term>
<term>Female</term>
<term>Health Surveys</term>
<term>Humans</term>
<term>Male</term>
<term>Pharmacovigilance</term>
<term>Research Design</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Bases de données pharmaceutiques</term>
<term>Causalité</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Enquêtes de santé</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pharmacovigilance</term>
<term>Plan de recherche</term>
<term>Systèmes de signalement des effets indésirables des médicaments</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The aim of this survey was to describe drug-induced immune thrombocytopenia (ITP) reported in the French PharmacoVigilance database (FPVD) and to discuss the drugs involved. The request to the FPVD used the seven most accurate diagnosis codes to identify ITP. The study was restricted to cases reported from 2007 to 2010 and at least "possible" according to the French causality assessment score. We then described the population's characteristics, the drugs involved, the clinical symptoms, and the course of ITP. For each drug, we estimated the causality assessment score developed by George for drug-induced ITP. We included 59 drug-induced ITP. Among them, 45.8% were post-vaccinal: they mainly occurred in children (median age: 16 years). Main vaccines were diphtheria-tetanus-poliomyelitis (DTP, 9 cases), influenza (n=8) and measles, mumps, and rubella (MMR, n=7). Regarding the 33 non-vaccinal cases: some drugs are well-known as triggering ITP (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), n=5; abciximab, n=4, acetaminophen, n=2). Other drugs inducing ITP were involved, like serotonin reuptake inhibitors or bevacizumab. Mean age was 57.1 ± 21.7; 60.6% of the patients were male and 25% had autoimmune antecedents. Among the 55 suspected drugs, three were classified as "probable" and 28 as "possible" according to George scale. In both vaccinal and other cases, median delay was 14 days, median platelet value at nadir was<10000 µl(-1) and hemorrhagic symptoms were rarely severe (only 2 gastrointestinal hemorrhages). Specific treatment was introduced in 45 (76.3%) patients. Five drug-induced cases led to chronicity. Among them, ezetimibe was suspected in two reports. In the FPVD, DTP, MMR, and influenza vaccines are the most often reported vaccines inducing ITP, perhaps because of their wide use. Our study confirmed that NSAIDs, abciximab, and acetaminophen frequently trigger ITP. It also allows to suspect other drugs like serotonin reuptake inhibitors or bevacizumab. Ezetimibe may induce chronic ITP. Drug-induced ITP is rarely severe. Finally, this study also shows that chronicity of ITP does not rule out the possibility of an iatrogenic cause.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22098130</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>12</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>08</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1369-1635</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>23</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>Platelets</Title>
<ISOAbbreviation>Platelets</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.</ArticleTitle>
<Pagination>
<MedlinePgn>490-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3109/09537104.2011.633179</ELocationID>
<Abstract>
<AbstractText>The aim of this survey was to describe drug-induced immune thrombocytopenia (ITP) reported in the French PharmacoVigilance database (FPVD) and to discuss the drugs involved. The request to the FPVD used the seven most accurate diagnosis codes to identify ITP. The study was restricted to cases reported from 2007 to 2010 and at least "possible" according to the French causality assessment score. We then described the population's characteristics, the drugs involved, the clinical symptoms, and the course of ITP. For each drug, we estimated the causality assessment score developed by George for drug-induced ITP. We included 59 drug-induced ITP. Among them, 45.8% were post-vaccinal: they mainly occurred in children (median age: 16 years). Main vaccines were diphtheria-tetanus-poliomyelitis (DTP, 9 cases), influenza (n=8) and measles, mumps, and rubella (MMR, n=7). Regarding the 33 non-vaccinal cases: some drugs are well-known as triggering ITP (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), n=5; abciximab, n=4, acetaminophen, n=2). Other drugs inducing ITP were involved, like serotonin reuptake inhibitors or bevacizumab. Mean age was 57.1 ± 21.7; 60.6% of the patients were male and 25% had autoimmune antecedents. Among the 55 suspected drugs, three were classified as "probable" and 28 as "possible" according to George scale. In both vaccinal and other cases, median delay was 14 days, median platelet value at nadir was<10000 µl(-1) and hemorrhagic symptoms were rarely severe (only 2 gastrointestinal hemorrhages). Specific treatment was introduced in 45 (76.3%) patients. Five drug-induced cases led to chronicity. Among them, ezetimibe was suspected in two reports. In the FPVD, DTP, MMR, and influenza vaccines are the most often reported vaccines inducing ITP, perhaps because of their wide use. Our study confirmed that NSAIDs, abciximab, and acetaminophen frequently trigger ITP. It also allows to suspect other drugs like serotonin reuptake inhibitors or bevacizumab. Ezetimibe may induce chronic ITP. Drug-induced ITP is rarely severe. Finally, this study also shows that chronicity of ITP does not rule out the possibility of an iatrogenic cause.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moulis</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Toulouse University Hospital, Toulouse, France. guillaume.moulis@univ-tlse3.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sommet</LastName>
<ForeName>Agnès</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sailler</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lapeyre-Mestre</LastName>
<ForeName>Maryse</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Montastruc</LastName>
<ForeName>Jean-Louis</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>French Association Of Regional Pharmacovigilance Centers</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>11</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Platelets</MedlineTA>
<NlmUniqueID>9208117</NlmUniqueID>
<ISSNLinking>0953-7104</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D062313" MajorTopicYN="N">Databases, Pharmaceutical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016553" MajorTopicYN="N">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22098130</ArticleId>
<ArticleId IdType="doi">10.3109/09537104.2011.633179</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement>
<li>Toulouse</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
<name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name>
</noCountry>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000336 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000336 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22098130
   |texte=   Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22098130" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeFranceV1 

Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Sun Aug 9 07:31:43 2020. Site generation: Thu Mar 25 22:05:26 2021